DPX-Survivac is Immunovaccine’s new T cell activating immunotherapy, while epacadostat (INCB24360) is Incyte’s investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor. Under the deal, both the firms will co-fund
Galafold is the first investigational Fabry drug to be granted accelerated assessment in the European Union (EU). In the US, the company plans to carry out a pre-NDA
The new facility will allow the company to complement its current ADC offering with full bio-conjugation services to meet increasing market demand. The investment in clinical and commercial
Under the deal, BioNTech’s subsidiaries, BioNTech RNA Pharmaceuticals and EUFETS, will work with Siemens to build a fully automated and digitalized production site to provide capacity for BioNTech’s
The ARMOR3-SV trial is being carried out for mCRPC patients whose tumors express the AR-V7 splice variant, which is a truncated form of the androgen receptor (AR) that
The acquisition also creates the most robust rare disease pipeline in the biotech industry across a range of therapeutic modalities. The deal was completed through a merger of
In the trial, patients received 12 weeks of Viekirax+ Exviera without ribavirin (RBV) and the results showed 100% sustained virologic response at 12 weeks post-treatment (SVR12) in these
Currently, Maruishi is applying for a manufacture and marketing license for Remifentanil injection, which is widely used as an opioid analgesic (µ-opioid receptor agonist) to manage general anaesthesia.
Around 84 subjects with late-prodromal or early-manifest HD will be included in the Phase III SIGNAL trial. The trial will be performed with the assistance of the Huntington
CDC’s Advisory Committee recommend that decisions to vaccinate adolescents and young adults of this age group against serogroup B meningococcal (MenB) disease should be made at the individual
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.